2024-09-06 - Analysis Report
## Vertex Pharmaceuticals (VRTX) Stock Analysis

**Company Overview:** Vertex Pharmaceuticals is a global biotechnology company focused on the development and commercialization of transformative therapies for serious diseases. 

**Performance Analysis:**

**1. Relative Performance:**

* VRTX has outperformed the S&P 500 (VOO) with a cumulative return of 141.66% compared to 89.66% for VOO. 
* The current outperformance relative to VOO stands at 52.0%, placing it at the 91.44th percentile based on historical data. This indicates VRTX has significantly outperformed the market historically.

**2. Recent Price Movement:**

* **Closing Price:** $495.89
* **5-Day Moving Average:** $488.38
* **20-Day Moving Average:** $478.45
* **60-Day Moving Average:** $482.04

The price is currently trading above all moving averages, indicating positive momentum.

**3. Technical Indicators:**

* **RSI:** 79.95 - This indicates the stock is currently in overbought territory.
* **PPO:** 0.39 - A positive PPO value suggests bullish momentum.
* **Delta_Previous_Relative_Divergence:** -6.98 - A negative value implies a short-term downward trend in relative performance.
* **Expected_Return:** 5.46% - This indicates a potential maximum 5-year expected return for current investments.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

The most recent earnings report showed a significant drop in EPS, which is concerning. However, it's crucial to consider any analyst expectations or guidance provided during the earnings call to understand the cause of the decline and its impact on future performance.

**Overall Analysis:**

VRTX has historically outperformed the market and currently shows positive price momentum. Technical indicators suggest overbought conditions, which could indicate a potential pullback in the near future. However, the stock remains in a strong uptrend. The most recent earnings report raises some concerns, and further analysis of the company's outlook is necessary to assess its future performance.

**Disclaimer:** This analysis is for informational purposes only and should not be considered as financial advice. It's essential to conduct thorough research and consult with a financial advisor before making any investment decisions.